Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04066296 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
This record was last updated October 1, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Record History
MinorChangedRegistry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
NotablePrimary completion date: Dec 31, 2023 to Dec 31, 2024Completion date: Jan 2024 to Jan 2025v5Show 1 more changeShow less
Completion date: Jan 2024 to Jan 2025
NotableTrial status: Not Yet Recruiting to RecruitingPrimary completion date: Dec 2021 to Dec 31, 2023 · Study sites: 0 to 1 · Completion date: Jan 2022 to Jan 2024 · 1 morev4Show 4 more changesShow less
Primary completion date: Dec 2021 to Dec 31, 2023
Study sites: 0 to 1
Completion date: Jan 2022 to Jan 2024
Start date changed from estimate of Sep 2021 to Sep 8, 2019
NotableStart date: Sep 2020 to Sep 2021Primary completion date: Sep 2021 to Dec 2021v3Show 1 more changeShow less
Primary completion date: Sep 2021 to Dec 2021
NotableStart date: Sep 2019 to Sep 2020v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate the benefit of using liposomal bupivicaine in lumbar laminectomies in terms of length of stay, IV narcotic use, 30-day narcotic use, visual analog score (VAS) and 30-day readmissions